# A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

> **NCT02963389** · PHASE1 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 27 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** Tripegfilgrastim

## Key facts

- **NCT ID:** NCT02963389
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-04
- **Primary completion:** 2018-11
- **Final completion:** 2018-11
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02963389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02963389, "A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02963389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*